Description

Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223.|[2]Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130.|[3]Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32.-CASNumber-1418200-58-4-MolecularWeight-144000 (average)-Compound Purity-98.72-SMILES-[Sofituzumab vedotin]-Research_Area-Cancer-Solubility-H2O-Target-Antibody-Drug Conjugates (ADCs)-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related